Endpoints for randomised controlled trials in systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 30, Issue 2, 2012, Pages 147-151

  Aringer, Martin ^a   Strand, Vibeke ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Endpoints; Health related quality of life; OMERACT; Randomised controlled clinical trials; Systemic lupus erythematosus

Indexed keywords

BRITISH ISLES LUPUS ASSESSMENT GROUP INDEX; DISEASE ACTIVITY; DRUG RESPONSE; EDITORIAL; EUROPEAN CONSENSUS LUPUS ACTIVITY MEASUREMENT; FACE VALIDITY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; OUTCOME ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SHORT FORM 36; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS RESPONDER INDEX;

ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84863750209     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (44)

1. NAVARRA SV, GUZMAN RM, GALLACHER AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.
2. FURIE R, PETRI M, ZAMANI O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30.
3. FURIE RA, PETRI MA, WALLACE DJ et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009; 61: 1143-51.
4. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
5. BENCIVELLI W, VITALI C, ISENBERG DA et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10: 549-54.
6. HAY EM, BACON PA, GORDON C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447-58.
7. MOSCA M, TANI C, ARINGER M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69: 1269-74.
8. SMOLEN JS, STRAND V, CARDIEL M et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 1999; 26: 504-7.
9. STRAND V, GLADMAN D, ISENBERG D, PETRI M, SMOLEN J, TUGWELL P Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus 2000; 9: 322-7.
10. STRAND V, CHU AD Measuring outcomes in systemic lupus erythematosus clinical trials. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 455-68.
11. YEE CS, CRESSWELL L, FAREWELL V et al. Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) 2010; 49:1665-9.
12. YEE CS, FAREWELL V, ISENBERG DA et al. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006; 54: 3300-5.
13. BRUCE IN, GORDON C, MERRILL JT, ISENBERG D Clinical trials in lupus: what have we learned so far? Rheumatology (Oxford) 2010; 49: 1025-7
14. YEE CS, FAREWELL VT, ISENBERG DA et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) 2011; 50: 982-8.
15. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004; 50: 3418-26.
16. GLADMAN DD, UROWITZ MB, KAGAL A, HALLETT D Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 2000; 27: 377-9.
17. TOUMA Z, UROWITZ MB, TAGHAVI-ZADEH S, IBANEZ D, GLADMAN D Systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) responder index 50 (SRI-50) identifies more responders than systemic lupus erythematosus responder index (SRI) at 6 and 12 months. Rheumatology (Oxford). In press 2012.
18. WALLACE DJ, STRAND V, FURIE R et al. Evaluation of treatment success in systemic lupus erythematosus clinical trials: development of the British Isles lupus assessment group-based composite lupus assessment endpoint. Arthritis Rheum 2011; 63 (10 Suppl.): S885-S886 [Abstract].
19. STRAND V, COOPER S, ZHONG ZJ, DENNIS G Responders in the phase 3 belimumab clinical trials in patients with systemic lupus erythematosus reported improvements in fatigue and health-related quality of life at week 52. Arthritis Rheum 2011; 63 (10 Suppl.): S535-S536 [Abstract].
20. VAN VOLLENHOVEN RF, ZAMANI O, WALLACE DJ et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. Ann Rheum Dis 2010; 69 (Suppl 3): 74 [Abstract].
21. ALETAHA D, LANDEWÉ R, KARONITSCH T et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ ACR collaborative recommendations. Arthritis Rheum 2008; 59: 1371-7.
22. SONG IH, RUDWALEIT M, LISTING J, SIEPER J Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis 2009; 68: 1701-7.
23. WITTKOWSKI KM, LEONARDI C, GOTTLIEB A et al. Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One 2011; 6: e20279.
24. GLADMAN DD, MEASE PJ, STRAND V et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007; 34: 1167-70.
25. HELLIWELL PS, FITZGERALD O, STRAND CV, MEASE PJ Composite Measures in Psoriatic Arthritis: a report from the GRAPPA 2009 annual meeting. J Rheumatol 2011; 38: 540-5.
26. HOUSSIAU FA, VASCONCELOS C, D'CRUZ D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing lowdose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-4.
27. CONTRERAS G, PARDO V, LECLERCQ B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-80.
28. GINZLER EM, DOOLEY MA, ARANOW C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-28.
29. APPEL GB, CONTRERAS G, DOOLEY MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-12.
30. GINZLER EM, APPEL GB, DOOLEY MA et al. Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva lupus management study (ALMS): efficacy by racial group. 2007 ACR program book supplement, 81 [Abstract].
31. DOOLEY MA, JAYNE D, GINZLER EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-95.
32. DAIKH DI, WOFSY D Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001; 166: 2913-6.
33. FURIE R, NICHOLLS K, CHENG T-T et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study. Arthritis Rheum 2011; 6 (10 Suppl.): S962-S963 [Abstract].
34. WOFSY D Abatacept for lupus nephritis: alternative outcome measures support opposing interpretations of data from a multicenter, randomized, double-blind, placebo-controlled phase II/III study. Arthritis Rheum 2011; 63 (10 Suppl.): S964-S965 [Abstract].
35. LOONEY RJ: B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs 2010; 70: 529-40.
36. FAVAS C, ISENBERG DA B-cell-depletion therapy in SLE-what are the current prospects for its acceptance? Nat Rev Rheumatol 2009; 5: 711-6
37. SMOLEN JS, STRAND V, CARDIEL M et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 1999; 26: 504-7.
38. THUMBOO J, STRAND V Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore 2007; 36: 115-22.
39. THUMBOO J, FONG KY Health-related quality of life of patients with systemic lupus erythematosus in Asia: how can this be improved? Lupus 2010; 19: 1430-5
40. BAUERNFEIND B, ARINGER M, PRODINGER B et al. Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. Arthritis Rheum 2009; 61: 21-8.
41. HANLY JG, UROWITZ MB, JACKSON D et al. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011; 70: 961-7.
42. YEE CS, MCELHONE K, TEH LS, GORDON C Assessment of disease activity and quality of life in systemic lupus erythematosus -new aspects. Best Pract Res Clin Rheumatol 2009; 23: 457-67.
43. MCELHONE K, CASTELINO M, ABBOTT J et al. The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J Rheumatol 2010; 37: 2273-9.
44. STRAND V, CHU AD Generic versus diseasespecific measures of health-related quality of life in systemic lupus erythematosus. J Rheumatol 2011; 38: 1821-3.